aser vs vaginal conjugated estrogen in postmenopausal wome
Not Applicable
Completed
- Conditions
- vulvovaginal atrophy.Postmenopausal atrophic vaginitis
- Registration Number
- IRCT2017050433817N1
- Lead Sponsor
- Ahvaz Jundishapur University of Medical Sciences, Research Development Unit0
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 130
Inclusion Criteria
(inclusion criteria: women's between 45-65 age suffering from Amenorrhea since 24 months; women's who diagnosed vaginally atrophy in clinical examination; women's who have sexual contract)
(exclusion criteria: women who treated with systemic estrogen since 6 months ago; history of cancer; pathologic change in the cervical Pap smear; Renal or liver failure; women taking estrogen therapy in past history; Radiation therapy of the vagina; vulvovaginitis; History of psychotropic drug or opium use)
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Vulvovaginal atrophy symptoms. Timepoint: at base line (day 0), 12 weeks post treatment. Method of measurement: visual analog scale measurement.
- Secondary Outcome Measures
Name Time Method Adverse events. Timepoint: at baseline ( day 0), 12 weeks post treatment. Method of measurement: according to patient history.;Female Sexual Function Index. Timepoint: at baseline ( day 0), 12 weeks post treatment. Method of measurement: according to Female Sexual Function Index.;Sexual satisfaction. Timepoint: at baseline ( day 0), 12 weeks post treatment. Method of measurement: visual analog scale measurement.